Want to see PDSB full AI Analyst Report?
Top Page
PDS Biotechnology
(NASDAQ:PDSB)
Select Model
Select Model
Rating:46Neutral
Price Target:
$0.21
▼(-3.64% Downside)
Action:Reiterated
Date:08/26/26
The score is held down primarily by weak financial performance (pre-revenue, ongoing losses/cash burn, and a notably weakened TTM balance sheet with negative equity and elevated debt) and a strongly bearish technical trend. Offsetting factors include a more positive earnings-call outlook driven by trial-design changes aimed at accelerating timelines and reducing costs, plus supportive corporate actions (strategy refocus and financing/listing developments), but these do not fully mitigate the financial and price-trend risks.
Positive Factors
Faster VERSATILE-003 development path
The protocol redesign may shorten the route to an interim readout, reduce trial costs and improve capital efficiency. Retaining overall survival for full approval preserves the program’s longer-term evidence strategy.
Negative Factors
Severe liquidity pressure
A very limited cash balance is a durable funding risk for a clinical-stage company with ongoing trials and no product revenue. Additional financing or partnering may be needed, creating execution uncertainty and potential dilution.
Read all positive and negative factors
Positive Factors
Negative Factors
Faster VERSATILE-003 development path
The protocol redesign may shorten the route to an interim readout, reduce trial costs and improve capital efficiency. Retaining overall survival for full approval preserves the program’s longer-term evidence strategy.
Read all positive factors
PDS Biotechnology (PDSB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$12.40M
Dividend YieldN/A
Average Volume (3M)397.42K
Price to Earnings (P/E)―
Beta (1Y)2.90
Revenue GrowthN/A
EPS Growth30.16%
CountryUS
Employees21
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.64
Shares Outstanding55,971,336
10 Day Avg. Volume238,945
30 Day Avg. Volume397,420
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)3.86
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$7.00Price Target Upside3081.82% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.47
Revenue Forecast (FY)N/A
PDS Biotechnology Business Overview & Revenue Model
Company Description
PDS Biotechnology Corporation is a clinical-stage biopharmaceutical firm dedicated to advancing innovative, multi-functional immunotherapies to combat cancer. Its primary drug candidate, PDS0101 (HPV16), is currently undergoing Phase II clinical t...
How the Company Makes Money
PDS Biotechnology is a clinical-stage company and does not have recurring product sales from approved therapies (null). Its revenue, when recognized, primarily comes from collaborations, strategic partnerships, and related arrangements such as lic...
PDS Biotechnology Earnings Call Summary
Earnings Call Date:May 13, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Nov 12, 2026
Earnings Call Sentiment Positive
The call conveyed meaningful clinical and intellectual property progress: a strategic protocol amendment for VERSATILE-003 that reduces patient count (~28.6%) and time to an interim readout, peer-reviewed and encouraging clinical data for PDS01ADC, strengthened IP extending PDS0101 protection into the 2040s, and established manufacturing processes. Financially, operating expenses and net loss improved year-over-year. Key risks include a relatively modest cash balance ($21.7M), continued unprofitability with rising interest expense, the need for OS data for full approval and additional confirmatory trials, and competition in the HPV16 head and neck space. On balance, the operational and clinical positives outweigh the near-term financial and development risks.Positive Updates
Protocol amendment for VERSATILE-003 to enable faster path to approval
Amended trial to add progression-free survival (PFS) as an interim co-primary endpoint while retaining overall survival (OS) for full approval; randomization changed from 2:1 to 1:1 and planned enrollment reduced from ~350 to ~250 patients (≈28.6% reduction), expected to shorten duration and lower trial costs and time to an interim readout.
Negative Updates
Cash balance and potential runway considerations
Cash on hand was $21.7M as of March 31, 2026; management did not provide explicit runway or guidance on financing needs, which could raise near-term funding questions given ongoing late-stage and development activities.
Read all updates
Q1-2026 Updates
Positive
Negative
Protocol amendment for VERSATILE-003 to enable faster path to approval
Amended trial to add progression-free survival (PFS) as an interim co-primary endpoint while retaining overall survival (OS) for full approval; randomization changed from 2:1 to 1:1 and planned enrollment reduced from ~350 to ~250 patients (≈28.6% reduction), expected to shorten duration and lower trial costs and time to an interim readout.
Read all positive updates
Company Guidance
Management guided that the VERSATILE‑003 amendment adopts progression‑free survival as an interim co‑primary endpoint (retaining overall survival for full approval) to enable a potential accelerated approval, changes randomization from 2:1 to 1:1 and reduces planned enrollment from ~350 to ~250 patients to shorten duration, lower external and internal costs and speed an interim readout (sites remained engaged and enrollment is restarting); they reiterated PDS0101’s differentiators (only late‑stage HPV16 HNSCC regimen that is subcutaneous and requires just five doses) and noted new U.S. and Japanese patents extending PDS0101 market protection into the 2040s. Financial metrics include cash of $21.7M as of March 31, 2026, a Q1 net loss of ~$7.3M ($0.13 per share) versus $8.5M ($0.21) year‑ago, R&D of $3.5M (vs $5.8M), G&A of $3.1M (vs $3.3M), total operating expenses of $6.5M (vs $9.1M) and net interest expense of $0.8M (vs $0.6M); operational guidance also highlighted an established Versamune manufacturing process with CMC validation/scale‑up ahead of a BLA and that PDS01ADC data (JCO Oncology Advances, NCI/AACR) support advancement—colorectal Stage 2 is fully enrolled with additional data expected by year‑end.PDS Biotechnology Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
6
Very Negative
Cash Flow
9
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | -59.79K | -57.33K | 0.00 | 0.00 |
| EBITDA | -27.13M | -30.30M | -33.75M | -40.09M | -40.74M | -21.43M |
| Net Income | -33.67M | -34.50M | -37.61M | -42.94M | -40.85M | -16.92M |
Balance Sheet | ||||||
| Total Assets | 8.81M | 30.49M | 45.36M | 59.39M | 77.01M | 67.20M |
| Cash, Cash Equivalents and Short-Term Investments | 5.60M | 26.71M | 41.69M | 56.56M | 73.82M | 65.24M |
| Total Debt | 4.36M | 16.93M | 21.83M | 23.85M | 23.47M | 490.35K |
| Total Liabilities | 12.39M | 21.24M | 26.35M | 33.26M | 33.01M | 3.99M |
| Stockholders Equity | -3.58M | 9.25M | 19.00M | 26.13M | 44.00M | 63.21M |
Cash Flow | ||||||
| Free Cash Flow | -7.17B | -27.75B | -35.06M | -33.64M | -25.71M | -12.49M |
| Operating Cash Flow | -7.17B | -27.75B | -35.03M | -33.64M | -25.71M | -12.49M |
| Investing Cash Flow | 0.00 | 0.00 | -29.00K | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | -13.95B | 12.77B | 20.19M | 16.38M | 34.29M | 48.89M |
PDS Biotechnology Technical Analysis
Negative
0.22
Price Trends
0.65
Negative
0.88
Negative
0.84
Negative
Market Momentum
-0.15
Positive
19.73
Positive
44.50
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PDSB, the sentiment is Negative. The current price of 0.22 is below the 20-day moving average (MA) of 0.42, below the 50-day MA of 0.65, and below the 200-day MA of 0.84, indicating a bearish trend. The MACD of -0.15 indicates Positive momentum. The RSI at 19.73 is Positive, neither overbought nor oversold. The STOCH value of 44.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PDSB.
PDS Biotechnology Risk Analysis
PDS Biotechnology disclosed 52 risk factors in its most recent earnings report. PDS Biotechnology reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
PDS Biotechnology Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $12.40M | -0.35 | -346.03% | ― | ― | 30.16% | |
46 Neutral | $27.87M | -1.35 | -456.35% | ― | ― | 9.68% | |
44 Neutral | $20.08M | -0.43 | 4092.98% | ― | ― | 15.37% | |
43 Neutral | $17.74M | -0.24 | -729.89% | ― | ― | 69.34% | |
42 Neutral | $12.17M | -0.22 | -503.79% | ― | ― | 80.28% |
* Healthcare Sector Average
PDSB
PDS Biotechnology
0.22
-1.02
-82.50%
TPST
Tempest Therapeutics
1.08
-8.77
-89.04%
LTRN
Lantern Pharma
2.16
-1.90
-46.80%
CALC
CalciMedica
0.47
-2.26
-82.78%
SNTI
Senti Biosciences
0.38
-1.17
-75.68%
PDS Biotechnology Corporate Events
Business Operations and StrategyExecutive/Board Changes
PDS Biotechnology Restructures Workforce and Leadership Team
Negative
Aug 25, 2026
On August 6, 2026, PDS Biotechnology’s board approved a significant reduction in force to better align operating expenses with its strategy around advancing PDS0301, beginning implementation and notifying affected employees on August 21, 202...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
PDS Biotechnology Shareholders Approve Expanded Authorized Stock
Positive
Aug 14, 2026
On August 10, 2026, PDS Biotechnology held its 2026 annual meeting of stockholders, where shareholders approved an amendment to the company’s certificate of incorporation doubling authorized common stock to 300,000,000 shares from 150,000,00...
Business Operations and Strategy
PDS Biotechnology Refocuses Strategy Around Lead Asset PDS0301
Positive
Aug 11, 2026
On August 11, 2026, PDS Biotechnology announced a strategic refocus following a board-led review of its portfolio and capital allocation, prioritizing development of its tumor-targeted immunocytokine PDS0301 in metastatic colorectal cancer and oth...
Business Operations and StrategyPrivate Placements and Financing
PDS Biotechnology Closes Financing and Retires Convertible Debentures
Positive
Jun 15, 2026
On April 30, 2026, PDS Biotechnology entered into a Securities Purchase Agreement with YA II PN, LTD. to issue a $6 million promissory note and a warrant to purchase up to 2,158,274 common shares at an exercise price of $1.1824 per share. On June ...
Regulatory Filings and ComplianceShareholder Meetings
PDS Biotechnology Sets 2026 Annual Stockholders Meeting Date
Neutral
Jun 15, 2026
PDS Biotechnology Corporation’s board of directors has scheduled the company’s 2026 Annual Meeting of Stockholders for August 10, 2026, with further details to be provided in a definitive proxy statement filed with the SEC. Because thi...
Delistings and Listing ChangesRegulatory Filings and Compliance
PDS Biotechnology Regains Nasdaq Compliance, Listing Risk Removed
Positive
Jun 2, 2026
On February 25, 2026, PDS Biotechnology disclosed that it had received a deficiency letter from Nasdaq after its common stock traded below the $1.00 minimum bid price for 30 consecutive business days, putting its continued listing on the Nasdaq Ca...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.